The world’s first life-saving gene therapy for children, developed by GlaxoSmithKline and Italian scientists, was approved for sale in Europe.
U.S. health officials reported the first case in the country of a patient with an infection resistant to all known antibiotics, and expressed grave concern that the superbug could pose serious danger for routine infections if it spreads.
Life sciences giant Thermo Fisher Scientific ponied up $4.2 billion to buy Oregon-based FEI Co., gaining access to that company’s electron microscopy technology.
Titan Pharmaceuticals announced that the U.S. FDA approved Probuphine (buprenorphine) implant for long-term maintenance of opioid dependence.
Biogen, Gilead Sciences, and Jazz Pharmaceuticals are the latest drug companies to disclose that they have received federal subpoenas related to their relationships with charitable nonprofits. Although there are few details, both Gilead and Jazz did say that the subpoenas were issued by the U.S. Attorney for the District of Massachusetts.
In what some may have seen as “turnaround is fair play,” embattled drugmaker Valeant Pharmaceuticals – known for its aggressive growth by mergers and acquisitions strategy – rejected a takeover bid from Takeda Pharmaceuticals and TPG Capital Management LP before the Joe Papa era began, Business Insider reported.
Interim data from a late-stage trial shows Genentech’s Gazyva for the treatment of untreated follicular lymphoma showed a significant difference in the staving off death or reducing the risk of disease progression when compared to Rituxan.
Starboard Value LP, one of the largest shareholders of Depomed Inc. with an ownership interest in approximately 9.9% of Depomed’s outstanding shares, announced it has delivered an open letter to Depomed shareholders and intends to recommence the process for calling a Special Meeting of Depomed shareholders for removing and replacing the current Depomed Board of Directors with a modified slate of six highly qualified director nominees.
Deerfield, Ill.-based Walgreens never vetted Theranos blood-testing technology before forming a partnership with the Palo-Alto, Calif. company, the Wall Street Journal reported.